Havah Therapeutics
Longmont, US · Founded 2023 · Delaware corporation
HavaH Therapeutics develops T+Ai, a subcutaneous extended-release pellet combining testosterone and anastrozole, aimed at preventing and treating hormone receptor positive breast cancer, including ductal carcinoma in situ (DCIS) and ER+ disease. The clinical-stage company targets the intra-mammary hormonal balance to slow tumor growth and reduce the need for surgery.
Founders & leadership
Havah Therapeutics was founded in 2023 by Stephen N Birrell.
SN
Stephen N BirrellFounder & Advisor
MB
Matt BrewerCEO & President
JA
John AdairCFO
RM
Ronald MartellNamed on SEC filing
JW
Jim WeissinBoard Member and Investor
Reported raises · per SEC filings
Form D private placements$507.4K disclosed across 1 round · 2024
▶$507.4KraisedMay 2024 · 14 investors · PharmaceuticalsRule 506(b)
▶$507.4KraisedMay 2024 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ronald MartellDirector
- Matthew BrewerExecutive Officer, Director
- Jim WeissDirector
- Offering amount
- $507.4K
- Amount sold
- $507.4K
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Havah Therapeutics do?
- HavaH Therapeutics develops T+Ai, a subcutaneous extended-release pellet combining testosterone and anastrozole, aimed at preventing and treating hormone receptor positive breast cancer, including ductal carcinoma in situ (DCIS) and ER+ disease. The clinical-stage company targets the intra-mammary hormonal balance to slow tumor growth and reduce the need for surgery.
- Who founded Havah Therapeutics?
- Havah Therapeutics was founded by Stephen N Birrell in 2023.
- How much funding has Havah Therapeutics raised?
- Havah Therapeutics has disclosed $507.4K raised across 1 round.
- Where is Havah Therapeutics headquartered?
- Havah Therapeutics is headquartered in Longmont, US.